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Although the annual mortality rate for end-stage renal disease (ESRD) is decreasing, likely
due to an increase in kidney transplantation rate, the survival probability for ESRD patients
from day one of dialysis has not changed, and is still poor with a 5-year survival rate of
approximately 34%. This is contributed to by a high prevalence of cardiovascular disease,
which is the leading cause of death in ESRD patients. In order to improve survival out-
comes, patients at high risk of cardiovascular related mortality need to be identiﬁed. Heart
rate variability (HRV), baroreceptor sensitivity, and baroreceptor reﬂex effectiveness index
can be used to assess heart rate control andmay predict cardiovascularmortality.This paper
will discuss how HRV, baroreceptor sensitivity, and baroreceptor reﬂex effectiveness index
are altered in renal disease and the utility of these indices as markers of cardiac risk in this
patient population.
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INTRODUCTION
Cardiovascular disease is highly prevalent chronic kidney disease
(CKD) and end-stage renal disease (ESRD) patients, and occurs
due to the development of vasculopathies, e.g., atherosclerosis or
arteriosclerosis, or cardiomyopathy, resulting in ischemic heart
disease or heart failure (Parfrey and Foley, 1999; Shamseddin
and Parfrey, 2011). The high incidence of cardiovascular dis-
ease in CKD/ESRD patients is due to a greater prevalence of
traditional cardiovascular risk factors, e.g., hypertension, hyper-
lipidemia, and diabetes, and risk factors associated with a chronic
uremic state, e.g., volume overload, anemia, and oxidative stress
(Parfrey and Foley, 1999). Consequently, cardiovascular disease
is the leading cause of death in ESRD patients, accounting for
∼40% of deaths in dialysis patients (U.S. Renal Data System,
2011).
Sudden cardiac death is the major cause of cardiac mortal-
ity in ESRD (Herzog, 2003; U.S. Renal Data System, 2011). The
incidence of sudden cardiac death increases as the stage of kid-
ney disease increases. In a retrospective study of renal disease
patients with coronary artery disease, the incidence of sudden car-
diac death was 3.8 events per 1000 patient-years in patients with
an estimated glomerular ﬁltration rate (eGFR)≥ 60ml/min, 7.3 in
patients with an eGFR between 15–59ml/min, and 24.2 in dialysis
patients (Pun et al., 2009). The prognosis for ESRD patients who
have been resuscitated following a cardiac arrest is abysmal, with
60% of patients dying in the ﬁrst 48-h (Karnik et al., 2001), and
a 30-day and 1-year survival rate of only 32 and 15%, respectively
(Herzog, 2003). Nevertheless, despite these disturbing statistics,
the high cardiovascular mortality rate in ESRD patients may be
reduced, as the use of angiotensin converting enzyme inhibitors
or angiotensin receptor blockers, independent of any antihyper-
tensive effect, is associated with a lower risk of mortality (Efrati
et al., 2002; Fang et al., 2008). In order to reduce the cardiac mor-
tality rate in ESRD, however, CKD or ESRD patients at a high risk
of cardiac death need to be identiﬁed early, to allow appropriate
clinical intervention.
Abnormalities in autonomic function, namely sympathetic
overdrive and parasympathetic insufﬁciency, play a key role in
the susceptibility to sudden cardiac death (Schwartz and Stone,
1980; Schwartz et al., 1988, 1992). There is now an overwhelming
amount of evidence showing the involvement of the autonomic
nervous system in the genesis of cardiovascular disease in CKD.
This includes sympathetic overactivity, as muscle (Converse et al.,
1992; Hausberg et al., 2002; Klein et al., 2003), but not skin (Park
et al., 2008; Grassi et al., 2009), sympathetic nerve activity is ele-
vated. The increase in muscle sympathetic nerve activity occurs
early in the disease progression (Grassi et al., 2011) and likely
increases the risk of mortality, as elevated plasma noradrenaline
levels are associated with both an increased risk of all-cause mor-
tality and cardiovascular events in ESRD patients without heart
failure (Zoccali et al., 2002). Conversely, parasympathetic nerve
activity is reduced, evidencedby reducedheart rate (HR) responses
to deep breathing, valsalva maneuver, and standing up (Agarwal
et al., 1991; Sahin et al., 2006). This sympatho-vagal imbalance
undoubtedly contributes to the increased risk of sudden cardiac
death in CKD/ESRD.
Heart rate variability (HRV) and baroreceptor reﬂex sensitiv-
ity (BRS) can be used to examine autonomic regulation of HR.
In myocardial infarction survivors, reduced HRV and BRS have
been shown to be highly predictive of an increased risk of cardiac
mortality (La Rovere et al., 1998, 2001). This review will discuss
how HRV, BRS, and an additional measure of baroreﬂex function,
baroreceptor effectiveness index (BEI), are altered in renal disease,
and their utility in predicting cardiac risk in ESRD patients.
HEART RATE VARIABILITY
Heart rate variability reﬂects the ability of the sinoatrial node to
adaptively alter HR in response to sympathetic and parasympa-
thetic inputs, respiration, circadian rhythm, and hormonal and
thermoregulatory inﬂuences (Stauss, 2003). Inmanydisease states,
the sinoatrial node is less able to alter HR, and instead the heart
beats like a metronome. Irrespective of the underlying cause, a
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reduction in HRV may predict sudden cardiac death (Molgaard
et al., 1991; La Rovere et al., 2003; Kataoka et al., 2004).
Heart rate variability can be assessed in a variety of ways: time-
domain analysis (statistical or geometrical), frequency-domain
analysis, or non-linear methods (Task Force of the ESC and
NASPE, 1996). Statistical time- and frequency-domain analyses
of HRV are the most commonly used methods. Statistical time-
domain parameters of HRV include SDof all normal R–R intervals
(SDNN), SD of the average R–R interval in all 5-min segments
(SDANN), square root of the mean squared differences of succes-
sive R–R intervals (RMSDD), and the proportion of adjacent R–R
intervals that are more than 50ms apart (pNN50). Frequency-
domain indices of HRV include total (TP), high frequency (HF),
low frequency (LF), and very low frequency (VLF) power. Total
power and SDNN correlate, reﬂecting overall HRV. HF power,
RMSDD, and pNN50 are analogous and reﬂect vagal and respi-
ratory mediated changes in HR. LF power reﬂects the capacity
of both the parasympathetic and sympathetic nervous systems to
alter HR, and cardiovascular reﬂexes, such as the, baroreceptor
reﬂex to buffer changes in HR. VLF and SDANN reﬂect long-term
changes in HR (Task Force of the ESC and NASPE, 1996; Zaza
and Lombardi, 2001; Guzik et al., 2007). A summary of how the
various HRV indices are altered in CKD/ESRD is presented in
Table 1.
The Renal Research Institute-CKD study, a four center prospec-
tive cohort study of adults with moderate to severe CKD (stages
3–5), demonstrated that HRV decreased as renal disease severity
increased. In this study, SDNN, SDANN, VLF, and LF:HF power
was lower in stage 5 non-dialysis CKD patients compared with
stage 3 and 4 CKDpatients (Chandra et al., 2011). Furthermore, in
type 1 diabetics with overt nephropathy, SDNN, RMSSD, pNN50,
SDANN, and LF power are positively related to creatinine clear-
ance, such that a decline in creatinine clearance is associated with
a diminution of HRV (Burger et al., 2002). Thus, the progressive
decline in renal function that occurs in renal disease alters auto-
nomic and long-term regulation of HR, resulting in a reduction in
HRV.
Few studies have examined the difference in HRV parameters
between stage 4/5 non-dialysis CKD and dialysis patients. Those
that have demonstrate no difference in the spectral indices (i.e.,
TP, HF, and LF) between stage 4/5 non-dialysis CKD and dialysis
patients (Mylonopoulou et al., 2010; Roumelioti et al., 2010),while
time-domain indices (e.g., SDNN and SDANN) may increase in
dialysis patients (Mylonopoulou et al., 2010). The lack of differ-
ence in spectralHRV indicesmay indicate that the inhibitory effect
of renal disease on HRV has reached maximal levels prior to the
need for renal replacement therapy.
Several co-variates affect HRV estimates in ESRD/CKD
patients, the most signiﬁcant of which is diabetes. Regardless
of disease stage, diabetic CKD patients have lower HRV indices
(Yamanaka et al., 2005; Mylonopoulou et al., 2010; Chandra et al.,
2011). The combination of renal disease and diabetes has a greater
inhibitory effect on HRV than the presence of renal disease or
diabetes alone, with non-diabetic ESRD and diabetic patients hav-
ing similar HRV estimates (Mylonopoulou et al., 2010). The only
exception is HF power, which is comparable in diabetic and non-
diabetic ESRD patients (Mylonopoulou et al., 2010). High resting
HR, older age, elevated serum phosphorus levels, anemia, high
cholesterol levels, increased left ventricular mass index, and/or use
of beta-blockers are also associated with reduced HRV in CKD
and ESRD (Steinberg et al., 1998; Furuland et al., 2008; Chandra
et al., 2011).
One of the hypothesized causes for autonomic dysfunction,
which can result in reduced HRV and an increased risk of car-
diac mortality (La Rovere et al., 1998), in ESRD is a uremia
driven excitation of the renal afferent nerves. Accordingly, muscle
sympathetic nerve activity is lower in nephrectomized versus non-
nephrectomized ESRD patients (Converse et al., 1992). Further-
more, conversion from conventional to nocturnal hemodialysis,
which allows for a more aggressive correction of uremia, reduces
plasma noradrenaline levels (Chan et al., 2003). Uremic excita-
tion of renal afferents may also underlie reduced HRV. Acutely,
hemodialysis increases SDNN, SDANN and reduces the ratio of
LF to HF power (Giordano et al., 2001; Tong and Hou, 2007;
Mylonopoulou et al., 2010; Celik et al., 2011); whereas, conver-
sion from chronic to nocturnal hemodialysis increases HF power
and normalizes LF to HF ratio (Chan et al., 2004). Following
renal transplantation, there is an eventual improvement in HRV.
At 1month post-transplantation, HRV parameters are similar to
pre-transplantation levels (Yang et al., 2010), while from 5 to
12months post-transplantation, LF, HF, TP, and SDNN are sim-
ilar to healthy control levels (Yildiz et al., 1998; Rubinger et al.,
2009; Yang et al., 2010). Nevertheless, such improvements are not
always reported (Kurata et al., 2004; Parisotto et al., 2008); whether
this reﬂects an insufﬁcient post-surgical recovery time (recovery
time 1–4+months) or other causes for reduced HRV in ESRD is
unknown.
The Renal Research Institute-CKD study concluded that a low
LF to HF ratio was associated with a higher risk of progression to
ESRD (Chandra et al., 2011) and the Atherosclerosis Risk in Com-
munities study highlighted the association between low LF and
HF power and the subsequent development of renal impairment,
even after correction for classical risk factors such as diabetes,
hypertension, and low baseline renal function (Brotman et al.,
2010). On the basis of this alone, reduced HRV values are pre-
dictive of a greater risk of mortality, whether cardiac related or
not, due to a higher risk of developing ESRD. Reduced HRV can
also predict an increased risk of cardiac mortality, with retro-
spective evidence existing that ESRD or CKD patients that died
of coronary artery disease, peripheral artery disease, congestive
heart failure, acute myocardial infarction, or a cardiac arrest, had
reduced HRV, notably low VLF, LF, and LF to HF ratio values,
compared with survivors (Fukuta et al., 2003a; Chandra et al.,
2011). Interestingly, ultra LF power, a rarely reported frequency-
domain parameter that reﬂects circadian rhythm changes in HR
(Stauss, 2003), is a highly sensitive parameter in predicting car-
diac related deaths (e.g., acute myocardial infarction, heart failure,
sudden cardiac death) in ESRD patients (Hayano et al., 1999;
Fukuta et al., 2003a,b), with values less than 8.7ms2, predictive
of sudden cardiac death (Hayano et al., 1999). Time-domain
estimates of HRV are also predictive of cardiac mortality, with
SDNN estimates less than 50ms reﬂective of a greater risk of
sudden cardiac death (Hathaway et al., 1998; Hayano et al.,
1999).
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Table 1 | Heart rate variability parameters in end-stage renal disease patients.
Reference Patient cohort HRV parameters
in ESRD patients
Comments
Celik et al. (2011) 31 ESRD patients on HD therapy
31 Healthy controls
Reduced SDNN
Reduced SDANN
Reduced RMSSD
Comparisons made with controls only following dialy-
sis therapy
Showed that HRV parameters improved following HD
therapy
Yang et al. (2010) 14 ESRD patients on HD therapy
14 Healthy controls
Reduced total power
Reduced LF power
Reduced HF power
Showed that all HRV parameters had improved by 6
months following renal transplantation
Giordano et al. (2001) 20 ESRD patients (9 diabetic) on HD
therapy
10 Healthy controls
Reduced total power
Increased LF (nu)
Reduced HF (nu)
Results shown here only include non-diabetic ESRD
patients
Total power and HF power lower in diabetic ESRD
patients
LF power higher in diabetic ESRD patients
Kurata et al. (2004) 13 ESRD patients on HD patients
10 Healthy controls
Reduced SDNN
Reduced rMSSD
Reduced LF power
Reduced HF power
Renal transplantation had no effect on HRV
parameters measured
Yang et al. (2010) 14 ESRD patients on HD that received
renal transplants
14 Healthy controls
Reduced total power
Reduced LF power
Reduced HF power
Renal transplant normalized reduction in total power
Renal transplant increased but did not normalize, LF
and HF power
Fukuta et al. (2003a) 120 ESRD patients on HD therapy
62 Healthy controls
Reduced SDNN
Reduced total power
Reduced ULF
Reduced VLF
Reduced LF power
Reduced HF power
Reduced VLF and ULF were predictive of cardiac
death
Rubinger et al. (2009) 52 ESRD patients on chronic HD therapy
44 ESRD patients with renal transplants
41 Healthy controls
Reduced LF power
Reduced HF power
LF power corrected 1 year following renal transplant
HF power not altered 1 year following renal transplant
Furuland et al. (2008) 16 Stage 4 CKD patients
16 Healthy controls
Reduced SDNN
Reduced SDANN
No change in rMSSD
No change in pNN50
Reduced total power
Reduced LF power
No change in HF power
Hemoglobin normalization corrected reduction in LF
and total power
Hemoglobin normalization did not affect time domain
estimates of HRV
Studinger et al. (2006) 14 Juvenille ESRD patients on HD
14 Juvenille renal transplant recipients
14 Healthy controls
Reduced RMSSD
Reduced LF power
No change in HF power
Renal transplant recipients showed no difference in
RMSSD or HF power
Steinberg et al. (1998) 66 ESRD patients (26 diabetic) on HD
33 Healthy controls
Reduced LF power
Reduced HF power
Diabetes was a major determinant for reduced LF
power
Age was a borderline signiﬁcant determinant for
reduced HF power
Yamanaka et al. (2005) 27 ESRD patients (13 diabetic) on HD
46 Healthy controls
Reduced LF power
Reduced HF power
LF and HF power was reduced further in diabetic
ESRD patients
BAROREFLEX SENSITIVITY AND EFFECTIVENESS
In comparisons to the numerous studies examining HRV in
CKD/ESRD patients, relatively little is known regarding barore-
ceptor reﬂex control of HR. This may reﬂect the methodology
required to investigate baroreceptor function, which requires a
blood pressure recording as opposed to the simple acquisition of
an ECG signal. It is not an indication, however, that assessing
baroreceptor reﬂex function is not a useful marker of cardiac risk.
On the contrary, reduced baroreceptor reﬂex control of HR has
been established as a strong predictor of cardiac mortality follow-
ing myocardial infarction (La Rovere et al., 1998), and in heart
failure patients (Mortara and Tavazzi, 1996).
Baroreceptor reﬂex control of HR can be assessed by exam-
ining the sensitivity of the reﬂex (BRS), i.e., the ability of the
www.frontiersin.org January 2012 | Volume 2 | Article 121 | 3
Hildreth Risk indicators in kidney disease
baroreceptor reﬂex to produce reﬂex bradycardia or tachycar-
dia. Alternatively, although not as utilized, the effectiveness of the
baroreceptor reﬂex (BEI), i.e., how often the baroreceptor reﬂex
produces a change in HR in response to a perturbation in blood
pressure, can be examined (Di Rienzo et al., 2001). High BRS and
BEI scores are reﬂective of healthy baroreceptor reﬂex control of
HR.
Baroreceptor reﬂex control of HR, as examined by BRS (Pick-
ering et al., 1972; Lazarus et al., 1973; Agarwal et al., 1991; Ger-
hardt et al., 1999; Gao et al., 2005; Studinger et al., 2006) and
BEI (Johansson et al., 2005, 2007), is impaired in renal disease
patients and may worsen as the disease severity increases. To date,
only two studies (Bavanandan et al., 2005; Lacy et al., 2006) have
examined BRS in moderate to severe non-diabetic CKD patients.
Both studies showed that BRS was positively correlated to GFR,
implying that BRS reduced as renal disease severity increases
(i.e., GFR decreased). Furthermore, Lacy et al. (2006) demon-
strated that BRS was lower in stage 4 CKD patients compared with
stage 3 CKD patients. However, neither study included a control
group. Therefore, it is still unknown at which point in the disease
process baroreceptor reﬂex control of HR alters. In addition to
the impact of worsening renal function, additional co-morbidities
may have additive negative effects on baroreceptor reﬂex function,
with greater reductions in BRS and BEI noted in diabetic versus
non-diabetic ESRD patients (Johansson et al., 2005).
The decline in BRS and BEI in ESRD can be reversed as conver-
sion from chronic to nocturnal hemodialysis increases BRS and
BEI (Chan et al., 2005, 2008). This is hypothesized to result from
an increase in arterial compliance as the improvement in BRS that
follows conversion to nocturnal hemodialysis is positively corre-
lated with an increase in stroke volume to pulse pressure ratio
(Chan et al., 2005). Furthermore, following renal transplantation,
BRS and BEI is increased to control levels (Studinger et al., 2006;
Rubinger et al., 2009).
The exact cause(s) of impaired baroreceptor reﬂex function in
ESRD is unknown, but may relate, in part, to an inability for the
baroreceptors to sense changes in blood pressure. This could arise
from vascular stiffness in the aortic arch and carotid sinus, the ori-
gin of baroreceptor afferents, as BRS is negatively correlated with
increased carotid artery stiffness (Studinger et al., 2006) and an
increase in vascular calciﬁcation, albeit in the superﬁcial femoral
artery, in dialysis patients (Chesterton et al., 2005). Alternatively,
it could be due to abnormal central processing of the baroreceptor
reﬂex or an inability for the cardiac vagal or sympathetic efferents
to produce effective changes in HR.
Despite the limited number of studies examining BRS and
BEI in ESRD patients, a reduction in these parameters confers
an increased risk of mortality. Reduced BEI is an independent
predictor of all-cause mortality, while reduced BRS, an indepen-
dent predictor of sudden cardiac death (Johansson et al., 2007).
The impact of reduced BRS in ESRD is not limited to a poten-
tial predisposition to life threatening arrhythmias. A reduction
in BRS may also contribute to hemodialysis related hypoten-
sion, a signiﬁcant cause of mortality in hemodialysis patients, due
to an inability to counteract dialysis induced volume depletion
(Heber et al., 1989; Chesterton et al., 2010). Further studies are
required, however, to verify and strengthen the use of BRS as
a predictive marker of an increased risk of cardiac mortality in
CKD/ESRD.
CONCLUSION
Heart rate variability, BRS, and BEI are reduced in ESRD patients.
These three parameters convey different information regarding
cardiovascular health and may provide independent indications
of a greater risk of cardiovascular mortality. Although individ-
ual HRV parameters are inconsistently reported as reduced in
CKD/ESRD patients, a simple estimation of overall HRV (SDNN)
can easily identify CKD/ESRD patients at risk of sudden cardiac
death. Comparatively little is known regarding baroreceptor reﬂex
function in CKD. Nevertheless, BRS and BEI have been shown
to predict sudden cardiac death and all-cause mortality in ESRD
patients respectively.
REFERENCES
Agarwal, A., Anand, I. S., Sakhuja, V.,
and Chugh, K. S. (1991). Effect
of dialysis and renal transplanta-
tion on autonomic dysfunction in
chronic renal failure. Kidney Int. 40,
489–495.
Bavanandan, S., Ajayi, S., Fentum, B.,
Paul, S. K., Carr, S. J., and Robin-
son,T.G. (2005). Cardiac barorecep-
tor sensitivity: a prognostic marker
in predialysis chronic kidney dis-
ease patients[quest]. Kidney Int. 67,
1019–1027.
Brotman, D. J., Bash, L. D., Qayyum, R.,
Crews, D., Whitsel, E. A., Astor, B.
C., and Coresh, J. (2010). Heart rate
variability predicts ESRD and CKD-
related hospitalization. J. Am. Soc.
Nephrol. 21, 1560–1570.
Burger, A. J., D’elia, J. A., Wein-
rauch, L. A., Lerman, I., and Gaur,
A. (2002). Marked abnormalities
in heart rate variability are associ-
ated with progressive deterioration
of renal function in type I diabetic
patients with overt nephropathy. Int.
J. Cardiol. 86, 281–287.
Celik,A.,Melek,M.,Yuksel, S.,Onrat,E.,
and Avsar, A. (2011). Cardiac auto-
nomic dysfunction in hemodial-
ysis patients: the value of heart
rate turbulence. Hemodial. Int. 15,
193–199.
Chan, C. T., Hanly, P., Gabor, J., Pic-
ton, P., Pierratos, A., and Floras,
J. S. (2004). Impact of nocturnal
hemodialysis on the variability of
heart rate and duration of hypox-
emia during sleep. Kidney Int. 65,
661–665.
Chan,C. T.,Harvey, P. J., Picton, P., Pier-
ratos,A.,Miller, J. A., and Floras, J. S.
(2003). Short-term blood pressure,
noradrenergic, and vascular effects
of nocturnal home hemodialysis.
Hypertension 42, 925–931.
Chan,C. T., Jain,V., Picton, P., Pierratos,
A., and Floras, J. S. (2005). Noc-
turnal hemodialysis increases arter-
ial baroreﬂex sensitivity and compli-
ance and normalizes blood pressure
of hypertensive patients with end-
stage renal disease. Kidney Int. 68,
338–344.
Chan, C. T., Shen, X. S., Picton,
P., and Floras, J. (2008). Noctur-
nal home hemodialysis improves
baroreﬂex effectiveness index of
end-stage renal disease patients. J.
Hypertens. 26, 1795–1800.
Chandra, P., Sands, R. L., Gillespie, B.
W., Levin, N. W., Kotanko, P., Kiser,
M., Finkelstein, F., Hinderliter, A.,
Pop-Busui, R., Rajagopalan, S., and
Saran, R. (2011). Predictors of heart
rate variability and its prognostic
signiﬁcance in chronic kidney dis-
ease. Nephrol. Dial. Transplant. doi:
10.1093/ndt/gfr340
Chesterton, L. J., Selby, N. M., Bur-
ton, J. O., Fialova, J., Chan, C., and
Mcintyre, C. W. (2010). Categoriza-
tion of the hemodynamic response
to hemodialysis: the importance of
baroreﬂex sensitivity. Hemodial. Int.
14, 18–28.
Chesterton, L. J., Sigrist, M. K., Bennett,
T., Taal, M. W., and Mcintyre, C. W.
(2005). Reduced baroreﬂex sensitiv-
ity is associated with increased vas-
cular calciﬁcation and arterial stiff-
ness. Nephrol. Dial. Transplant. 20,
1140–1147.
Converse, R. L., Jacobsen, T. N., Toto,
R. D., Jost, C. M. T., Cosentino, F.,
Fouad-Tarazi, F., and Victor, R. G.
(1992). Sympathetic overactivity in
Frontiers in Physiology | Integrative Physiology January 2012 | Volume 2 | Article 121 | 4
Hildreth Risk indicators in kidney disease
patients with chronic renal failure.
N. Eng. J. Med. 327, 1912–1918.
Di Rienzo,M., Parati, G., Castiglioni, P.,
Tordi, R., Mancia, G., and Pedotti,
A. (2001). Baroreﬂex effectiveness
index: an additional measure of
baroreﬂex control of heart rate in
daily life.Am. J. Physiol. Regul. Integr.
Comp. Physiol. 280, R744–R751.
Efrati, S., Zaidenstein, R., Dishy, V.,
Beberashvili, I., Sharist, M., Aver-
bukh, Z., Golik, A., andWeissgarten,
J. (2002). ACE inhibitors and sur-
vival of hemodialysis patients. Am.
J. Kidney Dis. 40, 1023–1029.
Fang, W., Oreopoulos, D. G., and
Bargman, J. M. (2008). Use of ACE
inhibitors or angiotensin receptor
blockers and survival in patients
on peritoneal dialysis. Nephrol. Dial.
Transplant. 23, 3704–3710.
Fukuta, H., Hayano, J., Ishihara, S.,
Sakata, S., Mukai, S., Ohte, N.,
Ojika, K., Yagi, K., Matsumoto,
H., Sohmiya, S., and Kimura, G.
(2003a). Prognostic value of heart
rate variability in patients with
end-stage renal disease on chronic
haemodialysis. Nephrol. Dial. Trans-
plant. 18, 318–325.
Fukuta, H., Hayano, J., Ishihara, S.,
Sakata, S., Ohte, N., Takahashi, H.,
Yokoya, M., Toriyama, T., Kawa-
hara, H., Yajima, K., Kobayashi, K.,
and Kimura, G. (2003b). Prognostic
value of nonlinear heart rate dynam-
ics in hemodialysis patients with
coronary artery disease. Kidney Int.
64, 641–648.
Furuland,H.,Linde,T.,Englund,A., and
Wikstrom,B. (2008).Heart rate vari-
ability is decreased in chronic kidney
disease butmay improvewith hemo-
globin normalization. J. Nephrol. 21,
45–52.
Gao, S. A., Johansson, M., Hammaren,
A., Nordberg, M., and Friberg, P.
(2005). Reproducibility of methods
for assessing baroreﬂex sensitivity
and temporal QT variability in end-
stage renal disease and healthy sub-
jects. Clin. Auton. Res. 15, 21–28.
Gerhardt, U., Riedasch, M., Steinmetz,
M., and Hohage, H. (1999). Kidney
transplantation improves barore-
ceptor sensitivity. Int. J. Cardiol. 70,
233–239.
Giordano, M., Manzella, D., Paolisso,
G., Caliendo, A., Varricchio, M., and
Giordano, C. (2001). Differences
in heart rate variability parameters
during the post-dialytic period in
type II diabetic and non-diabetic
ESRD patients. Nephrol. Dial. Trans-
plant. 16, 566–573.
Grassi, G., Quarti-Trevano, F., Seravalle,
G.,Arenare, F.,Volpe,M., Furiani, S.,
Dell’oro, R., and Mancia, G. (2011).
Early sympathetic activation in the
initial clinical stages of chronic renal
failure. Hypertension 57, 846–851.
Grassi,G., Seravalle,G.,Arenare,F.,Buc-
cianti,G.,Furiani, S., Ilardo,V.,Bolla,
G., and Mancia, G. (2009). Behav-
iour of regional adrenergic outﬂow
in mild-to-moderate renal failure. J.
Hypertens. 27, 562–566.
Guzik, P., Piskorski, J., Krauze, T.,
Schneider, R., Wesseling, K. H.,
Wykretowicz, A., and Wysocki, H.
(2007). Correlations between the
Poincare plot and conventional
heart rate variability parameters
assessed during paced breathing. J.
Physiol. Sci. 57, 63–71.
Hathaway, D. K., Cashion, A. K., Mil-
stead, E. J., Winsett, R. P., Cowan,
P. A., Wicks, M. N., and Gaber, A.
O. (1998). Autonomic dysregulation
in patients awaiting kidney trans-
plantation. Am. J. Kidney Dis. 32,
221–229.
Hausberg,M., Kosch,M.,Harmelink, P.,
Barenbrock,M.,Hohage,H., Kisters,
K., Dietl, K. H., and Rahn, K. H.
(2002). Sympathetic nerve activity in
end-stage renal disease. Circulation
106, 1974–1979.
Hayano, J., Takahashi, H., Toriyama,
T., Mukai, S., Okada, A., Sakata, S.,
Yamada,A., Ohte,N., and Kawahara,
H. (1999). Prognostic value of heart
rate variability during long-term
follow-up in chronic haemodialysis
patients with end-stage renal dis-
ease. Nephrol. Dial. Transplant. 14,
1480–1488.
Heber, M. E., Lahiri, A., Thompson, D.,
and Raftery, E. B. (1989). Barore-
ceptor, not left ventricular, dysfunc-
tion is the cause of hemodialy-
sis hypotension. Clin. Nephrol. 32,
79–86.
Herzog, C. A. (2003). Cardiac arrest in
dialysis patients: approaches to alter
an abysmal outcome. Kidney Int. 63,
S197–S200.
Johansson, M., Gao, S. A., Friberg, P.,
Annerstedt,M., Bergstrom,G., Carl-
strom, J., Ivarsson, T., Jensen, G.,
Ljungman, S., Mathillas, O., Nielsen,
F.-D., and Strombom, U. (2005).
Reduced baroreﬂex effectiveness
index in hypertensive patients with
chronic renal failure[ast]. Am. J.
Hypertens. 18, 995–1000.
Johansson, M., Gao, S. A., Friberg, P.,
Annerstedt, M., Carlstrom, J., Ivars-
son, T., Jensen, G., Ljungman, S.,
Mathillas, O., Nielsen, F. D., and
Strombom, U. (2007). Baroreﬂex
effectiveness index and baroreﬂex
sensitivity predict all-cause mortal-
ity and sudden death in hypertensive
patients with chronic renal failure. J.
Hypertens. 25, 163–168.
Karnik, J. A., Young, B. S., Lew, N. L.,
Herget, M., Dubinsky, C., Lazarus,
J. M., and Chertow, G. M. (2001).
Cardiac arrest and sudden death
in dialysis units. Kidney Int. 60,
350–357.
Kataoka,M., Ito, C., Sasaki, H., Yamane,
K., and Kohno, N. (2004). Low heart
rate variability is a risk factor for sud-
den cardiac death in type 2 diabetes.
Diabetes Res. Clin. Pract. 64, 51–58.
Klein, I. H., Ligtenberg, G., Neumann,
J., Oey, P. L., Koomans, H. A.,
and Blankestijn, P. J. (2003). Sym-
pathetic nerve activity is inappro-
priately increased in chronic renal
disease. J. Am. Soc. Nephrol. 14,
3239–3244.
Kurata, C., Uehara, A., and Ishikawa,
A. (2004). Improvement of cardiac
sympathetic innervation by renal
transplantation. J. Nucl. Med. 45,
1114–1120.
La Rovere,M. T., Bigger, J. T. Jr.,Marcus,
F. I., Mortara, A., and Schwartz, P.
J. (1998). Baroreﬂex sensitivity and
heart-rate variability inpredictionof
total cardiac mortality after myocar-
dial infarction. ATRAMI (Auto-
nomic Tone and Reﬂexes After
Myocardial Infarction) Investiga-
tors. Lancet 351, 478–484.
La Rovere, M. T., Pinna, G. D., Hohn-
loser, S. H., Marcus, F. I., Mor-
tara, A., Nohara, R., Bigger, J. T.
Jr., Camm, A. J., and Schwartz, P.
J. (2001). Baroreﬂex sensitivity and
heart rate variability in the iden-
tiﬁcation of patients at risk for
life-threatening arrhythmias: impli-
cations for clinical trials. Circulation
103, 2072–2077.
La Rovere, M. T., Pinna, G. D., Maestri,
R., Mortara, A., Capomolla, S.,
Febo, O., Ferrari, R., Franchini, M.,
Gnemmi, M., Opasich, C., Riccardi,
P. G., Traversi, E., and Cobelli, F.
(2003). Short-term heart rate vari-
ability strongly predicts sudden car-
diac death in chronic heart failure
patients. Circulation 107, 565–570.
Lacy, P., Carr, S. J., O’brien, D., Fen-
tum, B., Williams, B., Paul, S. K.,
andRobinson,T.G. (2006). Reduced
glomerular ﬁltration rate in pre-
dialysis non-diabetic chronic kid-
ney disease patients is associated
with impaired baroreceptor sensi-
tivity and reduced vascular compli-
ance. Clin. Sci. 110, 101–108.
Lazarus, J.M.,Hampers,C. L.,Lowrie,E.
G., and Merrill, J. P. (1973). Barore-
ceptor activity in normotensive and
hypertensive uremic patients. Circu-
lation 47, 1015–1021.
Molgaard, H., Sorensen, K. E., and Bjer-
regaard, P. (1991). Attenuated 24-h
heart rate variability in apparently
healthy subjects, subsequently suf-
fering sudden cardiac death. Clin.
Auton. Res. 1, 233–237.
Mortara, A., and Tavazzi, L. (1996).
Prognostic implications of auto-
nomic nervous system analysis in
chronic heart failure: role of heart
rate variability and baroreﬂex sen-
sitivity. Arch. Gerontol. Geriatr. 23,
265–275.
Mylonopoulou, M., Tentolouris, N.,
Antonopoulos, S., Mikros, S., Kat-
saros, K.,Melidonis, A., Sevastos, N.,
and Katsilambros, N. (2010). Heart
rate variability in advanced chronic
kidney disease with or without dia-
betes: midterm effects of the initia-
tion of chronic haemodialysis ther-
apy. Nephrol. Dial. Transplant. 25,
3749–3754.
Parfrey, P. S., and Foley, R. N. (1999).
The clinical epidemiology of cardiac
disease in chronic renal failure. J.
Am. Soc. Nephrol. 10, 1606–1615.
Parisotto, V., Lima, E. M., Silva, J. M.,
De Sousa, M. R., and Ribeiro, A. L.
(2008). Cardiac sympathetic dysau-
tonomia in children with chronic
kidney disease. J. Nucl. Cardiol. 15,
246–254.
Park, J., Campese, V. M., Nobakht, N.,
and Middlekauff, H. R. (2008). Dif-
ferential distribution of muscle and
skin sympathetic nerve activity in
patientswith end-stage renal disease.
J. Appl. Physiol. 105, 1873–1876.
Pickering, T. G., Gribbin, B., and Oliver,
D. O. (1972). Baroreﬂex sensitivity
in patients on long-term haemodial-
ysis. Clin. Sci. 43, 645–657.
Pun, P. H., Smarz, T. R., Honeycutt,
E. F., Shaw, L. K., Al-Khatib, S.
M., and Middleton, J. P. (2009).
Chronic kidney disease is associated
with increased risk of sudden cardiac
death among patients with coro-
nary artery disease. Kidney Int. 76,
652–658.
Roumelioti, M. E., Ranpuria, R., Hall,
M., Hotchkiss, J. R., Chan, C. T.,
Unruh, M. L., and Argyropou-
los, C. (2010). Abnormal noctur-
nal heart rate variability response
among chronic kidney disease and
dialysis patients during wakefulness
and sleep. Nephrol. Dial. Transplant.
25, 3733–3741.
Rubinger, D., Backenroth, R., and
Sapoznikov, D. (2009). Restoration
of baroreﬂex function in patients
with end-stage renal disease after
renal transplantation. Nephrol. Dial.
Transplant. 24, 1305–1313.
Sahin, M., Kayatas, M., Urun, Y., Sen-
naroglu, E., and Akdur, S. (2006).
Performing only one cardiovascular
reﬂex test has a high positive predic-
tive value for diagnosing autonomic
www.frontiersin.org January 2012 | Volume 2 | Article 121 | 5
Hildreth Risk indicators in kidney disease
neuropathy in patients with chronic
renal failure on hemodialysis. Ren.
Fail. 28, 383–387.
Schwartz, P. J., La Rovere, M. T., and
Vanoli, E. (1992). Autonomic ner-
vous system and sudden cardiac
death. Experimental basis and clini-
cal observations for post-myocardial
infarction risk stratiﬁcation. Circu-
lation 85, I77–I91.
Schwartz, P. J., and Stone, H. L.
(1980). Left stellectomy in the pre-
vention of ventricular ﬁbrillation
caused by acutemyocardial ischemia
in conscious dogs with anterior
myocardial infarction. Circulation
62, 1256–1265.
Schwartz, P. J., Vanoli, E., Stramba-
Badiale, M., De Ferrari, G. M., Bill-
man, G. E., and Foreman, R. D.
(1988). Autonomicmechanisms and
sudden death. New insights from
analysis of baroreceptor reﬂexes in
conscious dogs with and without
a myocardial infarction. Circulation
78, 969–979.
Shamseddin, M. K., and Parfrey, P.
S. (2011). Sudden cardiac death
in chronic kidney disease: epidemi-
ology and prevention. Nat. Rev.
Nephrol. 7, 145–154.
Stauss, H. M. (2003). Heart rate vari-
ability. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 285, R927–R931.
Steinberg, A. A., Mars, R. L., Goldman,
D. S., andPercy,R. F. (1998). Effect of
end-stage renal disease on decreased
heart rate variability. Am. J. Cardiol.
82, 1156–1158, A1110.
Studinger, P., Lenard, Z., Mersich, B.,
Reusz, G. S., and Kollai, M. (2006).
Determinants of baroreﬂex function
in juvenile end-stage renal disease.
Kidney Int. 69, 2236–2242.
Task Force of the ESC and NASPE.
(1996). Heart rate variability:
standards of measurement, physi-
ological interpretation and clinical
use. Circulation 93, 1043–1065.
Tong, Y. Q., and Hou, H. M.
(2007). Alteration of heart rate
variability parameters in nondia-
betic hemodialysis patients. Am. J.
Nephrol. 27, 63–69.
U.S. Renal Data System. (2011). USRDS
2011 Annual Data Report: Atlas of
Chronic Kidney Disease and End-
Stage Renal Disease in the United
States. Bethesda,MD:National Insti-
tutes of Health, National Institute of
Diabetes and Digestive and Kidney
Diseases.
Yamanaka, N., Aoyama, T., Ikeda,
N., Higashihara, M., and Kamata,
K. (2005). Characteristics of heart
rate variability entropy and blood
pressure during hemodialysis in
patientswith end-stage renal disease.
Hemodial. Int. 9, 303–308.
Yang, Y. W., Wu, C. H., Tsai, M. K.,
Kuo, T. B., Yang, C. C., and Lee, P.
H. (2010). Heart rate variability dur-
ing hemodialysis and following renal
transplantation.Transplant. Proc. 42,
1637–1640.
Yildiz, A., Sever, M. S., Demirel, S.,
Akkaya, V., Turk, S., Turkmen, A.,
Ecder, T., and Ark, E. (1998).
Improvement of uremic autonomic
dysfunction after renal transplanta-
tion: a heart rate variability study.
Nephron 80, 57–60.
Zaza,A., and Lombardi, F. (2001). Auto-
nomic indexes based on the analysis
of heart rate variability: a view from
the sinus node. Cardiovasc. Res. 50,
434–442.
Zoccali, C., Mallamaci, F., Parlongo, S.,
Cutrupi, S., Benedetto, F. A., Tripepi,
G., Bonanno, G., Rapisarda, F.,
Fatuzzo, P., Seminara, G., Cataliotti,
A., Stancanelli, B., and Malatino, L.
S. (2002). Plasma norepinephrine
predicts survival and incident car-
diovascular events in patients with
end-stage renal disease. Circulation
105, 1354–1359.
Conﬂict of Interest Statement: The
author declares that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 30October 2011; paper pending
published: 17 November 2011; accepted:
20 December 2011; published online: 12
January 2012.
Citation: Hildreth CM (2012) Prognos-
tic indicators of cardiovascular risk in
renal disease. Front. Physio. 2:121. doi:
10.3389/fphys.2011.00121
This article was submitted to Frontiers
in Integrative Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Hildreth. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
Frontiers in Physiology | Integrative Physiology January 2012 | Volume 2 | Article 121 | 6
